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bjectives We sought to conduct a meta-analysis to compare N-acetylcysteine (NAC) in combina-
ion with sodium bicarbonate (NaHCO3) for the prevention of contrast-induced acute kidney injury
AKI).
ackground Contrast-induced AKI is a serious consequence of cardiac catheterizations and percuta-
eous coronary interventions (PCI). Despite recent supporting evidence for combination therapy, not
nough has been done to prevent the occurrence of contrast-induced AKI prophylactically.
ethods Published randomized controlled trial data were collected from OVID/PubMed, Web of
cience, and conference abstracts. The outcome of interest was contrast-induced AKI, deﬁned as a
25% or 0.5 mg/dl increase in serum creatinine from baseline. Secondary outcome was renal fail-
re requiring dialysis.
esults Ten randomized controlled trials met our criteria. Combination treatment of NAC with in-
ravenous NaHCO3 reduced contrast-induced AKI by 35% (relative risk: 0.65; 95% conﬁdence interval:
.40 to 1.05). However, the combination of N-acetylcysteine plus NaHCO3 did not signiﬁcantly re-
uce renal failure requiring dialysis (relative risk: 0.47; 95% conﬁdence interval: 0.16 to 1.41).
onclusions Combination prophylaxis with NAC and NaHCO3 substantially reduced the occur-
ence of contrast-induced AKI overall but not dialysis-dependent renal failure. Combination pro-
hylaxis should be incorporated for all high-risk patients (emergent cases or patients with
hronic kidney disease) and should be strongly considered for all interventional radio-contrast
rocedures. (J Am Coll Cardiol Intv 2009;2:1116–24) © 2009 by the American College of
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1117ontrast-induced acute kidney injury (AKI) is a serious con-
equence of the more than 1.3 million cardiac catheterizations
nd percutaneous coronary interventions (PCI) in the U.S.
ach year. Researchers hypothesize contrast-induced AKI re-
ults from direct toxicity to the renal tubules by contrast
edium or renal hemodynamic changes (1,2). Up to 15% of
atients develop contrast-induced AKI after PCI with a
-fold increased risk of in-hospital (3) and long-term
ortality (4).
See page 1125
Contrast-induced AKI is commonly defined as a 25%
ncrease or 0.5 mg/dl increase in serum creatinine from
aseline within 48 h of exposure (4–7). Chertow et al. (8) and
ihal et al. (9) showed that contrast-induced AKI was associ-
ted with an increased risk of in-hospital mortality. Patients
ith contrast-induced AKI had a 22% mortality rate compared
ith 1.4% for those without AKI (9). Patients admitted to
he hospital for all causes and developing contrast-induced
KI were 6.5 times more likely to die in the hospital
ompared with patients not developing AKI; on average
hese patients had 3.5 more days in the hospital and $7,500
dditional hospital costs (8).
Variation exists in prophylactic strategies, and there is a lack
f consensus on prevention tactics according to a recent
askforce (10). Despite the ease of identifying patients at
isk (11,12), preventive measures to reduce contrast-induced
KI have not been consistent (13). However, 2 recent
andomized controlled trials (RCTs) among high-risk pa-
ients using N-acetylcysteine (NAC) and sodium bicarbon-
te (NaHCO3) (14,15) demonstrated the combination of
AC and NaHCO3 were significantly effective at prevent-
ng the contrast-induced AKI. Both NAC and NaHCO3
re oxygen-derived free radical scavengers and therefore
lock injury to the renal tubules (16–21). There has been no
ormal synthesis of the combination prophylactic trial data.
onsequently, there are no consensus protocols for prophy-
actic strategies or contrast dosing to prevent contrast-
nduced AKI. These gaps have identified opportunities to
dopt effective evidence-based measures to reduce contrast-
nduced AKI.
Therefore, we sought to synthesize RCT evidence for
rophylactic combination strategies incorporating oral or in-
ravenous NAC and intravenous NaHCO3 in cardiac cathe-
erization or PCI.
ethods
ata and sources of searches. We conducted a meta-
nalysis of RCTs with combination prophylaxis of NAC
nd NaHCO3 among patients undergoing catheterization
r PCI. MEDLINE (OVID and PubMed, 1960 through
ebruary 2009), Web of Knowledge, Cochrane Libraryatabases, and conference abstracts (American Heart Asso-
iation, American College of Cardiology, Transcatheter
ardiovascular Therapeutics, National Kidney Foundation,
merican Society of Nephrology Renal Week) were used to
dentify published RCTs from 2006 through February
009.
tudy selection. Key words used to search included: “N-
cetylcysteine” and “sodium bicarbonate” and “catheterization
r angiography or percutaneous coronary intervention or PCI.”
he search yielded 10 published human RCTs (Fig. 1, Table 1)
14,15,22–29). We searched the ClinicalTrials website; we
ound 1 additional trial: CONTRAST (COmbined
-Acetylcysteine and Bicarbonate in PCI To Reduce Adverse
ide Effect of contrasT) (Singapore). However, the trial is still
nrolling patients and has not reported the interim results.
ata abstraction and quality assessment. We abstracted data
rom the trials on contrast-induced AKI (defined as 25%,
0.5 mg/dl, 25%, and 0.5 mg/dl increase in creatinine
rom baseline) and renal failure (new onset of dialysis). We
ollowed the appropriate methods
or conducting a meta-analysis as
tipulated in the Quality of Re-
orting of Meta-analysis state-
ent (30). Two independent re-
iewers (J.B., C.B.) selected trials
or information outcomes and re-
orded data on spreadsheets. The
adad criteria were used to as-
ess study quality and were re-
orted with the study charac-
eristics (Table 1) (31).
ata synthesis and analysis. All
utcome comparisons and treat-
ent effects were calculated with
Abbreviations
and Acronyms
AKI  acute kidney injury
CI  confidence interval
NAC  N-acetylcysteine
NaHCO3  sodium
bicarbonate
PCI  percutaneous
coronary interventions
RCT  randomized
controlled trial
RR  relative risk
Cr  increase in serum
creatinine
49 Potentially relevant RCTs 
identified from MEDLINE
40 Web of Science
7 Conference abstracts
15 Reviewed for more 
detailed information
10 RCTs included in
meta-analysis
71 excluded: duplicates or 
not RCTs
5 withdrawn: combination 
treatment not present
Figure 1. Study SelectionRCT  randomized controlled trial.
Table 1. Study Characteristics
Author (Ref. #) (Yr)
Total
Patients
Treatment Group Control Group
Enrollment Criteria Blinding
Jadad (31)
Scoren Treatment Protocol n Control Protocol
Saidin et al. (28)
(2006)
57 29 Oral NAC plus NaHCO3. Oral NAC plus NaHCO3 2 h before
and 6 h after procedure.
28 Oral NAC plus normal saline. Oral NAC plus
normal saline 2 h before and 6 h after
procedure.
Coronary angiography or angioplasty,
CKD stages 2–4.
Double-blind 2
Briguori et al. (14)
(2007)
351 108 Oral NAC plus NaHCO3. Isotonic saline (0.9%) IV at 1 ml/
kg/h (0.5 ml/kg/h for EF40) for 12 h before and 12 h
after contrast exposure. Oral 1,200 mg NAC twice/day
for day before and after procedure with 154 mEq/l
NaHCO3 in dextrose and H2O (Merten Protocol) (37):
initial IV bolus 3 ml/kg/h for 1 h immediately before
contrast; during and for 6 h after contrast exposure
with same dose at 1 ml/kg/h.
111 Oral NAC plus IV hydration. Isotonic saline
(0.9%) IV at 1 ml/kg/h (0.5 ml/kg/h for
EF40) for 12 h before and 12 h after
contrast exposure. Oral 1,200 mg NAC
twice/day for day before and after
procedure.
Coronary and/or peripheral angiography
and/or angioplasty with chronic kidney
disease, Creatinine 2 mg/dl or
eGFR40 ml min1 1.73 m2,
age 18 yrs.
Double-blind 3
107 Oral NAC plus IV hydration plus IV ascorbic acid. Isotonic saline (0.9%) IV at 1 ml/kg/h
(0.5 ml/kg/h for EF40) for 12 h before and 12 h after contrast exposure. Oral 1,200
mg NAC twice/day for day before and after procedure with 3 g IV ascorbic acid 2 h
before contrast and 2 g the night and morning after contrast.
Double-blind 3
Heguilen et al. (23)
(2007)
27 9 Oral NAC plus NaHCO3. Oral 600 mg NAC twice/day for
day before and day of procedure with 154 mEq/l
NaHCO3 at 3 ml/kg/h for 1 h immediately before
procedure; and at 1 ml/kg/h for 6 h after procedure.
9 Oral NAC plus normal saline. Oral 600 mg
NAC twice/day for day before and day
of procedure with 154 mEq/l normal
saline at 3 ml/kg/h for 1 h immediately
before procedure; and at 1 ml/kg/h for
6 h after procedure.
Coronary angiography or angioplasty,
serum creatinine 1.25 (mg/dl),
eGFR 50 ml min 1 1.73 m2,
age 18 yrs.
Single-blind 2
Kim et al. (24) (2007) 100 31 Oral NAC plus NaHCO3. Oral 600 mg NAC twice/day for
2 days with 80 mEq/l NaHCO3 at 1 ml/kg/h for 12 h
before procedure and for 12 h after procedure.
20 Oral NAC plus normal saline. Oral 600 mg
NAC twice/day for 2 days with 80 mEq/l
normal saline at 1 ml/kg/h for 12 h
before procedure and for 12 h after
procedure.
Elective coronary angiography, serum
creatinine 1.5 (mg/dl), proteinuria
500 mg/day.
Single-blind 1
Lin et al. (25) (2007) 45 21 Oral NAC plus NaHCO3. Oral 600 mg NAC twice/day for
day of and day after procedure with 154 mEq/l
NaHCO3 at 3 ml/kg/h for 1 h before procedure and for
6 h after procedure.
24 Oral NAC plus normal saline. Oral 600 mg
NAC twice/day for day of and day after
procedure with 154 mEq/l normal saline
at 3 ml/kg/h for 1 h before procedure
and for 6 h after procedure.
Coronary angiography, angioplasty, serum
creatinine 2.0 (mg/dl).
Single-blind 1
Recio-Mayoral et al.
(15) (2007)
111 56 IV NAC plus NaHCO3. Initial IV bolus 5 ml/kg/h alkaline
saline with 154 mEq/l NaHCO3 in 5% glucose and H2O
plus 2,400 mg NAC in same solution over 1 h. After
contrast, same ﬂuids continued without NAC at 1.5 ml/
kg/h for 12 h plus 2 oral doses of 600 mg NAC the day
after contrast.
55 Oral NAC plus hydration. Isotonic saline
(0.9%) at 1 ml/kg/h for 12 h after
contrast plus 2 oral doses of 600 mg
NAC the day after contrast.
Patients with MI undergoing primary or
rescue PCI or high-risk NSTEMI
requiring urgent PCI.
Single-blind 2
Shaikh et al. (29)
(2007)
320 80 IV NAC plus NaHCO3. IV NAC with 154 mEq/l NaHCO3 at
3 ml/kg/h for 1 h before procedure and 1 ml/kg/h for
6 h after procedure.
81 IV NAC plus normal saline. IV NAC with
154 mEq/l normal saline at 3 ml/kg/h
for 1 h before procedure and 1 ml/kg/h
for 6 h after procedure.
High-risk catheterization. Single-blind 1
Continued on next page
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1119he Cochrane Collaborative software, RevMan 4.2.8 (Bal-
imore, Maryland). We calculated the I2 to evaluate the
ercentage of heterogeneity among all the trials incorpo-
ated in the summary estimate (32). Heterogeneity was
bserved in the 3 comparisons; therefore, we used random
ffects modeling. For all comparisons, a fixed effects relative
isk (RR) and 95% confidence interval (CI) was calculated
or each independent study and for the summary statistic.
ethods for the calculation of the aforementioned statistics
ave been reported previously (33,34).
esults
en trials met our eligibility criteria for combination ther-
py including NaHCO3 plus NAC before and after contrast
dministration (Table 1). All studies reported contrast-
nduced AKI as a 25% increase in serum creatinine; 4
eported contrast-induced AKI separately by 0.5 (mg/dl)
ncrease in serum creatinine. Nine studies compared com-
ination treatment (NaHCO3 and NAC) with NAC and
ydration with normal saline; 1 study compared combina-
ion therapy with NAC alone; 1 study compared combina-
ion therapy with NAC with normal saline and a separate
rm with NAC and ascorbic acid (we have included this arm
n the analysis).
Contrast-induced AKI was defined in 3 ways. The first
nalysis with contrast-induced AKI defined as a 25%
ncrease in serum creatinine (Cr) (Fig. 2A) demonstrated
hat the combination of NAC plus NaHCO3 did not
ignificantly reduce contrast-induced AKI (25% Cr) by
3% with the combined RR of 0.67 (95% CI: 0.42 to 1.07);
owever, this effect demonstrated a strong trend toward
rotection against contrast-induce AKI. Alternatively,
hen using an alternative definition for contrast-induced
KI (0.5 creatinine) (Fig. 2B), a statistically significant
enefit was observed for combination treatment with a
ignificant 69% reduction (RR: 0.31; 95% CI: 0.11 to
.87). When using the greater of the 2 definitions (25%
Cr and 0.5) (Fig. 2C), the results were similar to the
25%-Cr definition with a nonsignificant 35% reduc-
ion in contrast-induced AKI (RR: 0.65; 95% CI: 0.40 to
.05).
ialysis. When the combination of NAC and NaHCO3
as compared with control subjects or head-to-head with
AC, the combination treatment did not significantly
educe dialysis-dependent renal failure (RR: 0.47; 95% CI:
.16 to 1.41) (Fig. 3).
iscussion
e conducted a meta-analysis on the clinical effectiveness
f NAC in combination with intravenous NaHCO3 com-pared with NAC. We found 10 RCTs that met our criteria.T
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1120ollectively, combination treatment of NAC with intrave-
ous NaHCO3 reduced contrast-induced AKI by 35% (RR:
.65; 95% CI: 0.40 to 1.05). Therefore, combination treat-
ent with NAC plus NaHCO3 prevented contrast-induced
KI in 4 of 10 patients over NAC alone. However, the
ombination of NAC plus NaHCO3 did not significantly
educe renal failure requiring dialysis (RR: 0.47; 95% CI:
.16 to 1.41), although only 5 patients (0.7%) receiving the
ombination therapy went on dialysis compared with 11
1.6%) who received N-acetylcysteine.
Multiple strategies have been used independently to
Review: Contrast-Induced Acute Kidney Injury
Comparison:
Outcome:
N-Acetylcysteine and Sodium Bicarbonate versus N-Acetylcystein
Contrast-Induced Acute Kidney Injury by definition
Study NAC and Bicarb NS and NAC
or sub-category n/N n/N
CI-AKI: 25% Increase In Serum Creatinine From Baseline
Saidin              9/29               4/28        
Briguori (AA)  2/108             10/107       
Briguori 2/108             11/111       
Heguilen            1/9                1/9         
Kim                 5/31               5/20        
Lin                 4/21               6/24        
Recio-Mayoral       1/56              17/55        
Shaikh              8/80               8/81        
Brar                15/73              13/78        
Maioli 38/250             52/252       
Ruiz                2/32               4/32        
Subtotal (95% CI) 797                797
Total events: 87 (NAC and Bicarb), 131 (NAC)
Test for heterogeneity: Chi2 = 20.66, df = 10 (P = 0.02), I2 = 51.6%
Test for overall effect: Z = 1.68 (P = 0.09)
CI-AKI: 0.5 (mg/dL) Increase In Serum Creatinine From Baseline
Briguori (AA)  1/108             12/107       
Briguori 1/108             12/111       
Recio-Mayoral       1/56              12/55        
Brar                10/73              13/78        
Maioli  25/250             29/252       
Subtotal (95% CI) 595                603
Total events: 38 (NAC and Bicarb), 78 (NAC)
Test for heterogeneity: Chi2 = 15.43, df = 4 (P = 0.004), I2 = 74.1%
Test for overall effect: Z = 2.22 (P = 0.03)
CI-AKI 25% or 0.5 (mg/dL) Increase In Serum Creatinine From Baseline
Saidin              9/29               4/28        
Briguori (AA)  2/108             12/107       
Briguori 2/108             12/111       
Heguilen            1/9                1/9         
Kim                 5/31               5/20        
Lin                 4/21               6/24        
Recio-Mayoral       1/56              17/55        
Shaikh              8/80               8/81        
Brar                15/73              13/78        
Maioli  38/250             52/252       
Ruiz                2/32               4/32        
Subtotal (95% CI) 797                797
Total events: 87 (NAC and Bicarb), 134 (NAC)
Test for heterogeneity: Chi2 = 22.36, df = 10 (P = 0.01), I2 = 55.3%
Test for overall effect: Z = 1.76 (P = 0.08)
0.01
Favors N-Acetylc
With Sodium Bica
A
B
C
Figure 2. CI-AKI
Individual randomized controlled trials are listed in order by year of publicatio
tive increase in serum creatinine from baseline). (B) CI-AKI (0.5 mg/dl increas
serum creatinine from baseline). The size of each square denotes the weight
resents the combined RR at the center; opposing points of the diamond repre
sodium bicarbonate (Bicarb). AA  N-acetylcysteine plus ascorbic acid; NS  neduce contrast-induced AKI: hydration alone, NaHCO3 2lone, NAC alone, and others. However, there has been a
ack of consensus about the implementation of these strat-
gies in practice, likely due to much confusion about their
linical efficacy.
ydration. In a small prospective RCT, hydration with
.45% normal saline for 12 h before and after angiography
as been shown to be effective in reducing contrast-induced
KI by 65% (35). In a large prospective RCT, hydration
ith one-half isotonic (0.45%) or isotonic (0.9%) saline for
he morning before elective PCI and immediately before
mergency PCI reduced contrast-induced AKI by 0.7% and
R (random) Weight RR (random)
95% CI % 95% CI
4.15 2.17 [0.75, 6.25]        
2.73 0.20 [0.04, 0.88]        
2.76 0.19 [0.04, 0.82]        
1.14 1.00 [0.07, 13.64]       
3.96 0.65 [0.21, 1.95]        
3.89 0.76 [0.25, 2.34]        
1.80 0.06 [0.01, 0.42]        
4.70 1.01 [0.40, 2.57]        
6.01 1.23 [0.63, 2.41]        
7.56 0.74 [0.50, 1.08]        
2.43 0.50 [0.10, 2.54]        
41.11 0.67 [0.42, 1.07]
1.74 0.08 [0.01, 0.62]        
1.74 0.09 [0.01, 0.65]        
1.77 0.08 [0.01, 0.61]        
5.53 0.82 [0.38, 1.76]        
6.91 0.87 [0.52, 1.44]        
17.69 0.31 [0.11, 0.87]
4.15 2.17 [0.75, 6.25]        
2.79 0.17 [0.04, 0.72]        
2.78 0.17 [0.04, 0.75]        
1.14 1.00 [0.07, 13.64]       
3.96 0.65 [0.21, 1.95]        
3.89 0.76 [0.25, 2.34]        
1.80 0.06 [0.01, 0.42]        
4.70 1.01 [0.40, 2.57]        
6.01 1.23 [0.63, 2.41]        
7.56 0.74 [0.50, 1.08]        
2.43 0.50 [0.10, 2.54]        
41.19 0.65 [0.40, 1.05]
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1121aHCO3. Isotonic NaHCO3 through the alkalinization of
enal tubular fluid and subsequent reduction in free oxygen
adicals has shown beneficial results (although mixed) in
educing contrast-induced AKI. Merten et al. (37) reported
atients receiving isotonic (154 mEq/l) infusion of
aHCO3 before and after contrast administration (370 mg
odine/ml) had an 89% reduction in contrast-induced AKI
ompared with patients that received hydration with iso-
onic sodium chloride. Four recent meta-analyses (38–41)
valuating the protective effects of hydration with NaHCO3
ompared with hydration with normal saline have shown
aHCO3 to be more effective in preventing contrast-
nduced AKI by 54% to 63%: (RR: 0.37, 95% CI: 0.18 to
.74); (RR: 0.45; 95% CI: 0.26 to 0.79); (RR: 0.46; 95% CI:
.26 to 0.82); and (RR: 0.52; 95% CI: 0.34 to 0.80).
AC. NAC is postulated to act as a free radical scavenger.
epel et al. (42) was the first to report a protective effect of
AC (600 mg twice daily on the day before and day of
ntervention with one-half isotonic saline) in reducing
ontrast-induced AKI by 91%. Seven meta-analyses of
AC have shown beneficial treatment effects in reducing
ontrast-induced AKI (43–49). However, 5 meta-analyses
ere inconclusive (50–54). Marenzi et al. (55) demon-
trated a dose-dependent effect of NAC (600 mg intrave-
ously before and 600 mg orally twice daily for 48 h after),
hereby both single and double doses of NAC reduced
ontrast-induced AKI and in-hospital mortality, with the
ore beneficial treatment being the double dose of NAC in
atients undergoing primary PCI. Unfortunately, NAC
ight cause an artificial transient decline in serum creati-
ine without changing renal function, and therefore addi-
ional markers of renal function should be incorporated to
onfirm these effects, such as Cystatin C (45,56). Recently,
Review: Contrast-Induced Acute Kidney Injury
Comparison: N-Acetylcysteine and Sodium Bicarbonate versus N-Acetylcy
Outcome: Dialysis-Dependent Renal Failure                                         
Study NAC and Bicarb NS and NAC
or sub-category n/N n/N
Briguori (AA)  1/108              4/107       
Briguori 1/108              1/111       
Recio-Mayoral       1/56               3/55        
Brar                1/175              2/178       
Maioli 1/250              1/252       
Total (95% CI) 697                703
Total events: 5 (NAC and Bicarb), 11 (NAC)
Test for heterogeneity: Chi2 = 1.04, df = 4 (P = 0.90), I2 = 0%
Test for overall effect: Z = 1.35 (P = 0.18)
0.01
Favors N-A
With Sodiu
Figure 3. Renal Failure Requiring Dialysis
Individual randomized controlled trials are listed in order by year of publicatio
RR in calculating the combined RR. The diamond represents the combined RR
NAC plus Bicarb. Abbreviations as in Figure 2.elly et al. (57) performed a meta-analysis of NAC com- rared with hydration alone. They found that oral or
ntravenous NAC significantly reduced contrast-induced
KI by 38% when compared with hydration controls (RR:
.62; 95% CI: 0.44 to 0.88). Current systematic reviews and
eta-analyses have identified a statistically significant ben-
fit for either hydration with NaHCO3 or prophylaxis with
AC. Our meta-analysis focused on the question of com-
ined hydration and prophylaxis with both NaHCO3 and
AC, demonstrating a significant benefit for combination
rophylaxis over NAC with or without hydration alone.
Other pharmacological strategies have been used over the
ears. Theophylline causes arrhythmias and therefore is not
seful for cardiac patients. In a recent meta-analysis, Kelly
t al. (57) showed that theophylline, with a nonsignificant
ut impressive 51% reduction in contrast-induced AKI
RR: 0.49; 95% CI: 0.23 to 1.06); this report suggests a
romising protective effect for theophylline. Prostaglandins
an cause severe hypotension. Other agents include antiox-
dant ascorbic acid and trimetazidine, but limited evidence
as been reported on these agents for preventing contrast-
nduced AKI (58). Hypoperfusion of the kidney through
asoconstriction might play a role in contrast-induced AKI;
owever, vasodilators have not been shown to be successful
n reducing contrast-induced AKI. All 4 RCTs for dopa-
ine showed no benefit in reducing contrast-induced AKI
59–62). Two trials have reported on fenoldopam, neither
howing a protective effect against contrast-induced AKI
57,63,64). A meta-analysis demonstrated that renal re-
lacement therapy does not reduce the risk of contrast-
nduced AKI (0.97; 95% CI: 0.44 to 2.14) (65). Continuous
eno-venous hemofiltration after PCI in 1 study was not
hown to protect renal function (66). However, a recent trial
y Lee et al. (67) reported that prophylactic hemodialysis
RR (random) Weight RR (random)
95% CI % 95% CI
24.90 0.25 [0.03, 2.18]        
15.47 1.03 [0.07, 16.22]       
23.64 0.33 [0.04, 3.05]        
20.60 0.51 [0.05, 5.56]        
15.39 1.01 [0.06, 16.03]       
100.00 0.47 [0.16, 1.41]
.1 1 10 100
ysteine
rbonate Favors N-Acetylcysteine
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1122or chronic kidney disease patients undergoing coronary
ngiography.
There have been several hypotheses generated around the
harmacodynamics of NAC and NaHCO3. Merten et al.
37) postulated that alkalizing the renal tubule fluid with
aHCO3 might reduce acute tubule necrosis brought on by
ephrotoxic contrast media. In a recent study examining
enal cell apoptosis by contrast agents, Romano et al. (68)
roposed that NaHCO3 scavenges free radicals and the
resence of bicarbonate in the proximal convoluted tubules
ight work to either buffer the production of hydrogen
ation from cellular hypoxia or to drive sodium cation
eabsorption. However, they reported that NaHCO3 did
ot raise the pH of the media in vitro compared with
ontrast alone and postulated that the protective action of
aHCO3 works through a different mechanism than NAC
nd ascorbic acid and therefore provides an additive effect
68). Romano et al. (68) were able to demonstrate that
AC and ascorbic acid works in vitro on the proximal renal
ubule and prevents renal cell apoptosis but not NaHCO3.
his finding was supported by an earlier report by Briguori
t al. (69), showing that NAC works in a dose-dependent
anner. Our meta-analysis compares the additive effect of
aHCO3 with the use of NAC or ascorbic acid and
emonstrates a distinct advantage in reducing contrast-
nduced AKI. Although the mechanism of the prophylactic
ffect of NaHCO3 in the renal tubules is not confirmed,
ecause of the summary of evidence, there does seem to be
n additive effect either through more regimented hydration
r through free-radical scavenging in the renal tubules.
The barriers to reducing contrast-induced AKI after PCI
ave been due to inconsistencies in the RCT evidence and
eta-analysis reporting either NAC or NaHCO3. Cardiol-
gy and nephrology historically have compartmentalized
atient care within each discipline. These barriers create a
hasm between current practice and the best evidence-based
are for patients.
Additional trials are needed to comment on the clinical
ffectiveness of combination protocols for the prevention of
ontrast-induced AKI. Recommendations differ surround-
ng the prevention of contrast-induced AKI, and not
nough has been done to establish a working protocol to
revent contrast-induced AKI among all patients. Until a
arge-scale RCT can be conducted to evaluate the clinical
ffectiveness of these prophylactic strategies, clinical action
ust be taken on the evidence that exists. We recommend
hat a comprehensive prophylactic protocol needs to be
ncorporated into practice to prevent contrast-induced AKI,
ncorporating both NaHCO3 and NAC. We encourage
nstitutions to form a multidisciplinary team of nephrolo-
ists, cardiologists, and epidemiologists to work together to
evelop evidence-based benchmarks for high-quality care
nd standardize their prophylactic strategies in preventing
ontrast-induced AKI.eprint requests and correspondence: Dr. Jeremiah R. Brown,
linical Research Section, Dartmouth-Hitchcock Medical Center,
ne Medical Center Drive, Lebanon, New Hampshire 03756.
-mail: jbrown@Dartmouth.edu.
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